These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28523463)

  • 1. Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis.
    Yin W; Ouyang S; Luo Z; Zeng Q; Hu B; Xu L; Li Y; Xiao B; Yang H
    Inflammation; 2017 Aug; 40(4):1460-1473. PubMed ID: 28523463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines.
    Li XL; Liu Y; Cao LL; Li H; Yue LT; Wang S; Zhang M; Li XH; Dou YC; Duan RS
    Mol Cell Neurosci; 2013 Sep; 56():85-95. PubMed ID: 23541702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway.
    Li XL; Li H; Zhang M; Xu H; Yue LT; Zhang XX; Wang S; Wang CC; Li YB; Dou YC; Duan RS
    J Neuroinflammation; 2016 Jan; 13():8. PubMed ID: 26757900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.
    Yang H; Zhang Y; Wu M; Li J; Zhou W; Li G; Li X; Xiao B; Christadoss P
    Inflamm Res; 2010 Mar; 59(3):197-205. PubMed ID: 19768385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis.
    Bu N; Wu HQ; Zhang GL; Zhan SQ; Zhang R; Fan QY; Li YL; Zhai YF; Ren HW
    J Neuroimmunol; 2015 Aug; 285():71-5. PubMed ID: 26198922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells.
    Wang S; Li H; Zhang M; Yue LT; Wang CC; Zhang P; Liu Y; Duan RS
    Neurosci Lett; 2016 Jul; 626():25-34. PubMed ID: 27181511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
    Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
    Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis.
    Li H; Wang CC; Zhang M; Li XL; Zhang P; Yue LT; Miao S; Wang S; Liu Y; Li YB; Duan RS
    Mol Cell Neurosci; 2015 Sep; 68():284-92. PubMed ID: 26311508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes derived from statin-modified bone marrow dendritic cells increase thymus-derived natural regulatory T cells in experimental autoimmune myasthenia gravis.
    Zhang P; Liu RT; Du T; Yang CL; Liu YD; Ge MR; Zhang M; Li XL; Li H; Dou YC; Duan RS
    J Neuroinflammation; 2019 Nov; 16(1):202. PubMed ID: 31679515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells.
    Aricha R; Reuveni D; Fuchs S; Souroujon MC
    J Autoimmun; 2016 Feb; 67():57-64. PubMed ID: 26489998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.
    Zhang J; Jia G; Liu Q; Hu J; Yan M; Yang B; Yang H; Zhou W; Li J
    Immunology; 2015 Jan; 144(1):56-67. PubMed ID: 24962817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.
    Liu Y; Yang CL; Yang B; Du T; Li XL; Zhang P; Ge MR; Lian Y; Li H; Liu YD; Duan RS
    Int Immunopharmacol; 2021 Jul; 96():107511. PubMed ID: 33915521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating the expression of CD80/CD86 on dendritic cells to induce immune tolerance after xeno-islet transplantation.
    Ke N; Su A; Huang W; Szatmary P; Zhang Z
    Immunobiology; 2016 Jul; 221(7):803-12. PubMed ID: 26879762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis.
    Zhang P; Yang CL; Liu RT; Li H; Zhang M; Zhang N; Yue LT; Wang CC; Dou YC; Duan RS
    Mol Immunol; 2018 Feb; 94():200-208. PubMed ID: 29331804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference targeting Bcl-6 ameliorates experimental autoimmune myasthenia gravis in mice.
    Xin N; Fu L; Shao Z; Guo M; Zhang X; Zhang Y; Dou C; Zheng S; Shen X; Yao Y; Wang J; Wang J; Cui G; Liu Y; Geng D; Xiao C; Zhang Z; Dong R
    Mol Cell Neurosci; 2014 Jan; 58():85-94. PubMed ID: 24361642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
    Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
    Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin inhibits the pathogenic functions of AChR-specific B and Th17 cells by targeting miR-146a.
    Hao Y; Zhao W; Chang L; Chen X; Liu C; Liu Y; Hou L; Su Y; Xu H; Guo Y; Sun Q; Mu L; Wang J; Li H; Han J; Kong Q
    Immunol Lett; 2022 Oct; 250():29-40. PubMed ID: 36108773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis.
    Souroujon MC; Aricha R; Feferman T; Mizrachi K; Reuveni D; Fuchs S
    Ann N Y Acad Sci; 2012 Dec; 1274():120-6. PubMed ID: 23252906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.